Damian Lamb

Mr. Lamb is co-Founder and Managing Director of Genesys Capital.
With over 20 years experience in life sciences venture capital, he is one of Canada’s most experienced investors and company builders.
Since co-founding Genesys Capital in 2000, Mr. Lamb has been instrumental in raising over $300 million in venture capital funds, and has been involved in deploying over $250 million across 38 investments.
He currently serves on the Boards of Flosonics Medical and the Centre for Probe Development and Commercialization at McMaster University.
Mr. Lamb has served on the Board of Affinium Pharmaceuticals (acquired by Debiopharm), Ionalytics Corporation (acquired by Thermo Electron Corp.), Millenium Biologix (acquired by Medtronic) and was Chairman of the Board of Fusion Pharmaceuticals Inc., Profound Medical Corp.
and DELEX Therapeutics Inc. when it was sold to YM BioSciences (now Gilead).
Mr. Lamb works closely with Genesys investee companies to strategically position the companies to build value for shareholders.
Prior to co-founding Genesys Capital, Mr. Lamb was an Investment Manager with MDS Capital Corp.
He is a frequently invited speaker at biotechnology industry conferences.
Mr. Lamb graduated from McMaster University, Faculty of Health Sciences, with a Master of Science in Molecular Neurobiology and also holds an MBA from Queen’s University.